1. Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial. Issue 3 (18th January 2015) Authors: Kim, M. K.; Rhee, E.‐J.; Han, K. A.; Woo, A. C.; Lee, M.‐K.; Ku, B. J.; Chung, C. H.; Kim, K.‐A.; Lee, H. W.; Park, I. B.; Park, J. Y.; Chul Jang, H. C.; Park, K. S.; Jang, W. I.; Cha, B. Y. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 3(2015:Mar.) Page Start: 309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗